|
| Study | Year | Treatment | Control | Number (T/C) | Results report |
|
| Pu Shanji | 2017 | Routine treatment + nitroglycerin (ivgtt, qd) + ginkgo-damole (20 mL/d, ivgtt, qd) | Routine treatment + sodium nitroprusside (ivgtt, qd) + valsartan (80 mg, qd, po) | 43/43 | DBP, SBP, clinical efficacy, safety |
|
| Li Zhenfei | 2017 | Nitroglycerin (ivgtt, qd) + ginkgo-damole (20 mL/d, ivgtt, qd) + oral antihypertensive drugs | Sodium nitroprusside (ivgtt, qd) + oral antihypertensive drugs | 60/60 | DBP, SBP, clinical efficacy |
|
| Tan Shifeng | 2015 | Nitroglycerin (ivgtt, qd) + ginkgo-damole (20 mL/d, ivgtt, qd) | Sodium nitroprusside (ivgtt, qd) + oral antihypertensive drugs | 40/40 | DBP, SBP, clinical efficacy |
|
| Hu Shuhua | 2014 | Routine treatment + nitroglycerin (ivgtt, qd) + ginkgo-damole (20 mL/d, ivgtt, qd) | Routine treatment + sodium nitroprusside (ivgtt, qd) + valsartan (80 mg, qd, po) | 49/49 | DBP, SBP, clinical efficacy, safety |
|
| Li Jigui | 2014 | Nitroglycerin (ivgtt, qd) + ginkgo-damole (20 mL/d, ivgtt, qd) + oral antihypertensive drugs | Sodium nitroprusside (ivgtt, qd) + oral antihypertensive drugs | 48/48 | DBP, SBP, clinical efficacy, safety |
|
| Yuan Ge | 2008 | Nitroglycerin (ivgtt, qd) + ginkgo-damole (20 mL/d, ivgtt, qd) + oral antihypertensive drugs | Routine treatment + sodium nitroprusside (ivgtt, qd) + oral antihypertensive drugs | 32/29 | DBP, SBP, clinical efficacy, safety |
|
| SUN Yinghang | 2017 | Nitroglycerin (ivgtt, qd) + ginkgo-damole (20 mL/d, ivgtt, qd) + oral antihypertensive drugs | Sodium nitroprusside (ivgtt, qd) + oral antihypertensive drugs | 36/36 | DBP, SBP, clinical efficacy, safety |
|
| Jin Hua | 2015 | Routine treatment + nitroglycerin (ivgtt, qd) + ginkgo-damole (20 mL/d, ivgtt, qd) | Routine treatment + sodium nitroprusside (ivgtt, qd) + valsartan (80 mg, qd, po) | 70/70 | DBP, SBP, clinical efficacy |
|
| Sun Xuegong | 2016 | Nitroglycerin (ivgtt, qd) + ginkgo-damole (20 mL/d, ivgtt, qd) + oral antihypertensive drugs | Sodium nitroprusside (ivgtt, qd) + oral antihypertensive drugs | 46/46 | DBP, SBP, clinical efficacy |
|
| Chen Xishan | 2011 | Nitroglycerin (ivgtt, qd) + ginkgo-damole (20 mL/d, ivgtt, qd) + oral antihypertensive drugs | Sodium nitroprusside (ivgtt, qd) + oral antihypertensive drugs | 30/30 | DBP, SBP, clinical efficacy |
|
| Zhu Feijuan | 2017 | Nitroglycerin (ivgtt, qd) + ginkgo-damole (20 mL/d, ivgtt, qd) | Sodium nitroprusside (ivgtt, qd) + oral antihypertensive drugs | 40/40 | DBP, SBP, clinical efficacy, safety |
|
| Wang Junhong | 2016 | Routine treatment + nitroglycerin (ivgtt, qd) + ginkgo-damole (20 mL/d, ivgtt, qd) | Routine treatment + sodium nitroprusside (ivgtt, qd) + oral antihypertensive drugs | 45/45 | Clinical efficacy |
|
| Min Riuxue | 2015 | Mannitol 125–250 ml + nitroglycerin (5 mg/d, ivgtt, qd) + ginkgo-damole (20 mL/d, ivgtt, qd) + oral antihypertensive drugs | Mannitol 125–250 ml + sodium nitroprusside (50 mg/d, ivgtt, qd) + oral antihypertensive drugs | 31/31 | Clinical efficacy |
|
| Yu Qisheng | 2014 | Nitroglycerin (ivgtt, qd) + ginkgo-damole (20 mL/d, ivgtt, qd) | Sodium nitroprusside (ivgtt, qd) + oral antihypertensive drugs | 40/40 | Clinical efficacy |
|
| Xin Zhaoyang | 2013 | Nitroglycerin (ivgtt, qd) + ginkgo-damole (20 mL/d, ivgtt, qd) + oral antihypertensive drugs | Sodium nitroprusside (ivgtt, qd) + oral antihypertensive drugs | 90/90 | Clinical efficacy |
|
| Zhang Mingchao | 2016 | Routine treatment + nitroglycerin (5 mg/d, ivgtt, qd) + ginkgo-damole (20 mL/d, ivgtt, qd) + oral antihypertensive drugs | Routine treatment + sodium nitroprusside (ivgtt, qd) + oral antihypertensive drugs | 55/55 | Clinical efficacy, safety |
|
